Company

Partner

Amount (US$M)

Details

Date

Total: $184.5M (Year total: $605.46M)

Alkermes plc (Dublin)

Biogen Inc. (Cambridge, Mass.)

$50.00

Following Biogen's review of preliminary gastrointestinal tolerability data from the ongoing clinical program of BIIB-098 (diroximel fumarate)

6/7/18

Argenx NV (Breda, the Netherlands)

Abbvie Inc. (North Chicago)

$10.00

For achieving the second of two preclinical milestones toward an investigational new drug filing for ARGX-115, which binds specifically to glycoprotein A repetitions predominant that plays a key role in the regulation of production and release of active transforming growth factor beta

6/29/18

Evotec AG (Hamburg, Germany)

Sanofi SA (Paris)

$3.50

For reaching the second beta cell therapy milestone as part of their diabetes-focused strategic alliance

6/26/18

Galapagos NV (Mechelen, Belgium)

Gilead Sciences Inc. (Foster City, Calif.)

$15.00

For progression into phase III of the phase IIb/III SELECTION study testing filgotinib in ulcerative colitis

6/4/18

Incyte Corp. (Wilmington, Del.)

Eli Lilly and Co. (Indianapolis)

$100.00

For FDA approval of a 2-mg dose of the once-daily oral JAK 1/2 inhibitor baricitinib, to treat adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor inhibitors

6/4/18

Mundipharma International Corp. Ltd. (Cambridge, U.K.)

Orexo AB (Uppsala, Sweden)

$3.50

For the launch of Zubsolv (buprenorphine and naloxone sublingual tablet), for use in the treatment of opioid dependence, in the European Union

6/19/18

Tetraphase Pharmaceuticals Inc. (Watertown, Mass.)

Everest Medicines Ltd. (China)

$3.00

For filing an application with Chinese regulators to start the phase III trial of lead product eravacycline in complicated intra-abdominal infections

6/8/18


Notes

Currency conversions are based on exchange rates at the time of the deal.

This chart includes only biotech companies that develop therapeutics.